Välkommen till årsstämma 2013

Välkommen till årsstämma 2013 1

Årsstämma 2013 Cristina Glad Verkställande direktör 2

Det senaste året i sammandrag Avslutade studier TB-403: Rättigheterna återtogs från Roche. En strategisk översyn av produktkandidatens framtida möjligheter pågår. TB-402: Fortsatt utveckling avbruten efter att studieresultat rapporterats i fas IIb-studien. BI-204: Fortsatt utveckling avbruten då uppsatta effektmåtten i GLACIERstudien ej nåddes. Nya Samarbeten Ett forskningssamarbete ingicks med Cancer Research Technology, för utveckling av nya antikroppsläkemedel mot cancer. Ett samarbete med Servier inom antikroppsbaserad cancerterapi inleddes i januari. 3

Det senaste året i sammandrag (forts.) Nytt Fokus Tydligt indikationsfokus i bolagets verksamhet sedan all egen utveckling av antikroppsläkemedel koncentrerats till onkologi. Två nya produktkandidater utsågs för behandling av främst blodcancer. Finansiering och organisation En företrädesemission om 104,8 MSEK före transaktionskostnader avslutades framgångsrikt i april. Antalet anställda har reducerats till ca 50 personer. BI-505 Positiva resultat rapporterades från fas I studien. BI-505 tolererades väl och terapeutisk effekt indikerades. Den första patienten doserades i april i en första fas II studie. 4

BioInvents Produktportfölj Project Primary Indication Discovery Preclinic Phase I Phase II Partner Collaboration Proprietary Projects BI-505 Multiple Myeloma ADC-1013 Metastatic cancer BI-1206 Non Hodgkins lymphoma TAM Oncology undisclosed Hematologic cancer Partner's Projects undisclosed not disclosed Licensee undisclosed not disclosed Licensee undisclosed not disclosed Licensee undisclosed not disclosed Licensee undisclosed not disclosed Licensee >10 projects not disclosed Licensee 5

Proven track record in partnering and deal making Klinik Und Poliklinik für Kinderheilkunde 6

Innehåll Bolagsöversikt Marknadsöversikt Samarbetspartner Klinisk pipeline Ekonomi Framtiden 7

Monoclonal antibodies a sweet spot in pharma Fastest growing segment within pharma market (CAGR of 11%, antibody market 2013 US$ 60bln) Addresses unmet need in blockbuster indications such as oncology and inflammation Shows lower attrition and shorter development timelines Has longer product life cycles less exposed to generic competition and price decline Source: Datamonitor $ bln 70 60 50 40 30 20 10 0 Sales of therapeutic antibodies 2008 2013E 8

Revenue Model External Drug Programs n-coder & F.I.R.S.T BioInvent or Lead candidate Partner Research Funding Programs fully funded by partner License fees Milestones Up to $ 15m in future milestone payments per program Royalties Royalties on all product sales Payments increasing as products advance 10

Development Status External Drug Programs Partner The collaboration Access to n-coder under a license with Product License options BioInvent has selected one of the Product Candidates under development Access to n-coder under a license with Product License options BioInvent commissioned to select Product Candidates Access to n-coder under a license with Product License options Clinical tests starting in 2013* BioInvent selects Product Candidate in oncology Undisclosed Japanese partner BioInvent has selected Product Candidate and manufactures material for tox and clinical studies 11 *) BioInvent expectations based on current development plans

BioInvent Proprietary Pipeline Project Indication Research Preclinical development Phase I Phase I/II BI-505 Multiple Myeloma Results Jan 2013 2013 ADC-1013 Metastatic Cancer Toxicology 2013 2014 BI-1206 Non Hodgkins Lymphoma Toxicology 2014 2015 TAM Several cancers CD 2015 Undisclosed Hematological malignancies CD 2016 13

BI-505 to treat Multiple Myeloma Description Fully human high antibody isolated based on functional properties Developed for treatment of multiple myeloma Mode of action Forces cancer cells into suicide mode and engages patient immune-effector cells Targets Inter-Cellular Adhesion Molecule 1 (ICAM-1) Market opportunity Global prevalence 120.000 in western economies Current sales of MM drugs: USD 8bn Orphan Drug Designation in Europe and US Strategic positioning Status Mono- or combination therapy in early stage MM patients or Combination therapy in relapsed MM or in patients refractory to SoC Potentially improved side effect profile Phase I study with 35 relapsed/refractory patients reported in Jan: Advantageous safety profile, 24 % of patients on extended therapy had stable disease for at least 2 months Study in asymptomatic multiple myeloma initiated April 2013 14

BI-505 to treat Multiple Myeloma ICAM-1 Highly and homogenously expressed on MM cells Involved in MM pathogenesis Highly expressed on plasma cells potential to treat other plasma cell driven diseases (e.g., ITP, SLE) BI-505 Fully human high affinity anti-icam- 1 antibody Potent single agent in vivo antimyeloma activity Disseminated models State-of-the-art SCID-Hu model Enhanced in vivo anti-myeloma activity of SoC/BI-505 combination Macrophage dependent MoA in vivo Macrophages abundantly present in MM microenvironment and involved in drug resistance 15

BI-505: Combination therapy data RPMI-8226 subcutaneous MM model Tumor growth until day 60 Survival over 220 days U266 disseminated MM model The combination of BI-505 and Revlimid or Velcade significantly enhances the therapeutic effect in both models 16

BI-505 phase II study Population Patients with asymptomatic myeloma (called smoldering multiple myeloma ) Design Single agent treatment in up to 10 patients Evaluates disease activity following treatment with BI-505. Secondary objectives include safety, pharmacokinetics and assessment of biomarkers Background Unmet medical need ~10 % per year progress to symptomatic MM during the first 5 years* *) Mayo Clinic data 17

ADC-1013 to treat solid tumours Description Fully human antibody activating the immune system (particularly dendritic cells) to kill cancer cells Mode of action Immunostimulatory CD40 agonistic antibody Intra-tumoural administration for enhanced efficacy and reduced risk of side effects Market opportunity Start with lymphomas and certain other solid tumours Not restricted to tumours expressing the antigen Status Co-developed with Alligator Bioscience AB 50/50 split of costs and revenues Toxicology to be commenced 2013 18

ADC-1013 local immunotherapy Transgenic Mouse: Bladder Cancer Model MB49 Bladder cancer model, human CD40 negative (MB49) Human CD40 transgenic mouse Systemic immunotherapy: general immune activation limited by toxicity. Local immunotherapy: tumor selective immune activation with powerful effect but minimal toxicity. 19

BI-1206 in Non-Hodgkin Lymphoma Description Fully human antibody boosting antibody therapeutics such as: Rituxan (haematological malignancies) Mode of action Anti-CD32b antagonistic antibody Blocks rituximab internalisation improves rituximab efficacy Target highly expressed in NHL (including CLL) Market opportunity Add-on to Rituxan (rituximab, Roche) with sales of > USD 6bn* Status All rights retained by BioInvent Toxicology studies expected to be initiated 2014 Non-Hodgkin Lymphoma (including CLL) targeted as first indication *) Non-Hodgkin Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL) 20

Aktiekursutveckling 2012-01-01---2013-03-31 Antal aktieägare 2012-01-01: 6 099 2013-03-31: 6 848 22

Finansiellt sammandrag 2012 vs 2011 MSEK Nettoomsättning jan-dec 2012 43 jan-dec 2011 125 Engångskostnader om 50 MSEK under 2012 Forsknings- och utvecklingskostnader Försäljnings- och administrationskostnader -207-39 -164-33 Övriga rörelseintäkter och -kostnader 12 0,2 Rörelseresultat Finansnetto Årets resultat Likvida medel -191 3,3-188 100-72 4,6-67 174 23 Intäkter 2011 inkl. 108 MSEK milstolpsbetalningar Stora kliniska åtaganden avslutades under 2012 Antal anställda reducerades till 50 (87) Kostnader 2013 förväntas sjunka till under hälften av 2012 års nivå

Finansiellt sammandrag Q1 2013 vs Q1 2012 MSEK Nettoomsättning Forsknings- och utvecklingskostnader Försäljnings- och administrationskostnader jan-mars 2013 12-20 -6,3 jan-mars 2012 15-50 -8,2 Minskning av externa kostnader Q1 2013 på grund av ett mer omfattande kliniskt program under Q1 2012 Övriga rörelseintäkter och -kostnader 0,4 6,3 Rörelseresultat -14-38 Lägre personalkostnader Finansnetto Periodens resultat -0.2-14 0,7-37 Likvida medel 77 138 24

Strong Platform for the Future: Five years outlook Proprietary Drug Projects 3 projects passed clinical POC all partnered; one potentially close to market 5 projects in early clinical development 2-4 projects in preclinical development External Drug Projects 5 projects passed Clinical POC > 10 projects in early clinical development > 10 projects in preclinical development 26

Tack 27